Abstract
MicroRNAs (miRNAs), endogenous small noncoding RNAs (ncRNAs), play crucial roles in cancer development. Many studies have demonstrated that miRNAs can serve as diagnostic and therapeutic biomarkers for malignancies. Additionally, single nucleotide polymorphisms (SNPs) located in miRNA functional regions have been reported to be involved in cancer susceptibility. In this study, we investigated the associations between SNPs located in miRNA functional regions and colorectal cancer (CRC) susceptibility. We systematically screened all candidate miRNAs and their SNPs and then evaluated the relationships between the SNPs and CRC susceptibility in a Han Chinese population including 878 patients with CRC and 884 controls. Genotyping was performed by TaqMan assay. After comprehensively screening the miRNAs and SNPs, we elected to evaluate the association between SNP rs2682818 in miR‐618 and CRC susceptibility. We found that the AA and AC/AA genotypes of rs2682818 were associated with a decreased risk of CRC compared with the CC genotype (odds ratio (OR) = 0.54, 95% confidence interval (CI) = 0.37–0.79 for AA vs. CC in codominant model; OR = 0.82, 95% CI = 0.68–0.99 for AC/AA vs. CC in dominant model). However, we obtained no statically significant results in our subgroup analyses. SNP rs2682818 in miR‐618 has potential as a biomarker for individuals with high CRC susceptibility. Our findings need to be verified in studies including larger samples. Moreover, molecular functional studies of miR‐681 must be performed to confirm its relationship with CRC.
Highlights
Colorectal cancer (CRC) is the third most common cancer and one of the major causes of cancer-related morbidity and mortality globally [1]
The principle objective of this study was to determine the association between a miR-618 polymorphism and CRC susceptibility in a Han Chinese population
A lower susceptibility to CRC was noted among specimens with an rs2682818 AA or AC/AA genotype than among specimens with a CC genotype
Summary
Colorectal cancer (CRC) is the third most common cancer and one of the major causes of cancer-related morbidity and mortality globally [1]. The newest recommendations of the United States Preventive Services Task Force (USPSTF) state that CRC screening via colonoscopy, sigmoidoscopy, or fecal occult blood testing should start at 50 years of age and continue until 75 years of age [2]. Reports from both the USA and the UK [3, 4] have verified that colonoscopy and sigmoidoscopy are significantly beneficial with respect to the prevention and early diagnosis of CRC. Various oncogenes and tumor suppressors, such as KRAS, APC, BRAF, TP53, and SMAD4, have been identified by CRC-related studies and may be useful for diagnosing and treating CRC in the future [10, 11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
